Glass House Brands Inc.
GLASInvestment snapshot
Positive
0
BUY / PASS
Neutral / negative
2 / 14
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 13 investors flag at least one valuation criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | FAIL · Rank #2110 (Top 68.1%) | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL | FAIL | FAIL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | Annual history · FY 2025 Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Annual history · FY 2025 · Market data at 2026-11-01 Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Annual history · FY 2025 · Market data at 2026-11-01 Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-24 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-03-24 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✓ 4✗ 24▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / Book Value per Share1.4x✗Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio1.4x✓Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-9.8%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-9.8%, ROC=-6.9%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)9.1x✗Dreman< 8xValuation ReasonablenessOE Yield=-40.2%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-13.1%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=1.4x✓MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low100% of trailing low ($1.27)✓Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-24.78%; #4692/6340 (top 74.0%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+0.6177; #2469/6449 (top 38.3%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share1.67x✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change-27.0%✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+1.5205; #1318/5247 (top 25.1%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-13.14%; #3336/4519 (top 73.8%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-88.55%; #5964/6202 (top 96.2%)✗OshaughnessyTop 10% of eligible cross-section - Verdicts0% pass✗ 15▾
Split decision: 14 FAIL · 2 NEUTRAL
Overall verdict✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (0/7)✗GreenblattRank #2110✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (1/11)✗MungerFAIL (0/4)✗PabraiFAIL (1/3)✗AkreFAIL (0/6)✗MarksFAIL (1/5)✗AckmanFAIL (3/9)•TempletonNEUTRAL (5/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #2180/2370 (Top 92.0%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked) - Cash Flow10% pass✓ 2✗ 10▾
9 of 10 flag GLAS's cash flow — Buffett, Lynch, Dreman +6 more
Free Cash Flow Proxy$-41.8M✗BuffettPositive and growingFCF Positive and Growing$-15.7M✗LynchPositive and growingOperating Cash Flow$11.4M✓PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=3.59%, ROA=-9.31%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)9.1x✗Dreman< 8xP/E or FCF YieldFCF Yield=-13.1%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive2/6 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-15.1%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency3/6 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-15.7M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-13.14%; #3336/4519 (top 73.8%)✗OshaughnessyTop 10% of eligible cross-section - Profitability13% pass✓ 5✗ 30▾
14 of 16 flag GLAS's profitability — Graham, Buffett, Lynch +11 more
Positive EPS (10 years)0/7 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)1/7 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-38.5%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-9.1% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-41.8M✗BuffettPositive and growingEarnings Variance (10-yr CoV)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-40.1%✗Lynch> 15%EBIT / Enterprise Value-9.8%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-9.8%, ROC=-6.9%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-9.31%✗PiotroskiROA > 0ROA Change YoY0.17% -> -9.31% (delta: -9.48%)✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=3.59%, ROA=-9.31%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY48.5% -> 42.3%✗PiotroskiImproved YoYPre-Tax Income / Revenue-9.4%✗Dreman>= 8%Net Income / Shareholders' Equity-40.1%✗Dreman> 12%Margin of SafetyP/B=1.4x✓PabraiP/B < 1.5 or P/E < 15Return on Equity-49.7% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency1/6 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-9.1%✗Ackman>= 15%Net Income / Shareholders Equity-40.1%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-30.8% (2023) -> -9.1% (2025)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 50.3% -> 42.3%, operating margin -30.8% -> -9.1%✓SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-24.78%; #4692/6340 (top 74.0%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+24.16%; #1782/3702 (top 48.1%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity-40.11%; #4085/5226 (top 78.2%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.1075; #3567/5884 (top 60.6%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/6 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Growth13% pass✓ 3✗ 10▾
7 of 8 flag GLAS's growth — Graham, Lynch, Dreman +4 more
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: 84.0% vs Rev: -9.4%✗LynchInventory growth < Revenue growthEPS Growth Direction✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency1/6 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth24.9%✓Ackman>= 5%Positive EPS Growth Frequency✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 50.3% -> 42.3%, operating margin -30.8% -> -9.1%✓SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR30.4%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Efficiency13% pass✓ 2✗ 9▾
7 of 8 flag GLAS's efficiency — Graham, Buffett, Greenblatt +4 more
Current Ratio1.78✗Graham>= 2.0ROIC (3-5 yr avg)-15.1%✗Buffett> 10%ROIC - WACC-25.1%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-6.9%✗Greenblatt> 25%Current Ratio Change YoY0.99 -> 1.78✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.65x -> 0.57x✗PiotroskiImproved YoYCurrent Assets / Current Liabilities1.78✓Dreman> 1.5Return on Invested Capital-9.2%✗Munger> 15%ROIC (high and growing)FY2023: ROIC=-25.4%; FY2024: ROIC=2.6%; FY2025: ROIC=-9.2%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROICN/A (non-positive net income)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/5 years above 12% (latest -9.2%)✗SleepROIC > 12% in a majority of years - Debt & Leverage25% pass✓ 5✗ 10▾
9 of 12 flag GLAS's debt & leverage — Graham, Buffett, Lynch +6 more
Total Debt / Shareholders' Equity0.93✗Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00xLT Debt vs Net Current AssetsLT Debt $68.6M vs NCA $29.8M✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: 0.93, IC: -3.7x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity0.93✗Lynch< 0.33Cash - Long-term Debt$-48.8M✗LynchPositive preferredLT Debt / Total Assets Change16.28% -> 21.54%✗PiotroskiDecreased YoYCurrent Assets / Current Liabilities1.78✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)Debt Levels0.93✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-3.7x, D/EBITDA=N/A✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity0.93✓Ackman<= 1.0Negative debt-to-equity (higher means less debt)-0.9287; #3141/4210 (top 74.6%)✗AsnessTop 30% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 8.9% of shares last year, 13.8% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
| Metric | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|
| Market Cap | $119.7Mcurrent | $421.3Mest. | $446.6Mest. | $166.9Mest. | $195.8Mest. |
| Revenue | $182.0M↓9% | $200.9M↑25% | $160.8M↑89% | $84.9M↑34% | $63.2M |
| Operating Income | -$16.5M↓388% | $5.7M↑112% | -$49.5M↑12% | -$56.4M↓56% | -$36.2M |
| Net Income | -$29.7M↓5815% | $519.0K↑101% | -$98.3M↓199% | -$32.9M↑24% | -$43.1M |
| EPS (Diluted) | $-0.55↓162% | $-0.21↑87% | $-1.62↓86% | $-0.87↑23% | $-1.13 |
| Gross Margin | 42.3%↓13% | 48.5%↓4% | 50.3%↑106% | 24.4%↓2% | 25.0% |
| Operating Margin | -9.1%↓418% | 2.9%↑109% | -30.8%↑54% | -66.4%↓16% | -57.2% |
| ROE | -40.1%↓9084% | 0.4%↑100% | -109.5%↓462% | -19.5%↑18% | -23.7% |
| Total Debt | $68.7M↑18% | $58.2M↓9% | $64.1M↑2% | $62.7M↑40% | $44.9M |
| Shareholders' Equity | $73.9M↓36% | $116.2M↑29% | $89.8M↓47% | $168.9M↓7% | $182.1M |
| Current Ratio | 1.78↑80% | 0.99↑76% | 0.56↓22% | 0.72↓42% | 1.24 |
| Debt / Equity | 0.93↑85% | 0.50↓30% | 0.71↑92% | 0.37↑51% | 0.25 |
| Operating Cash Flow | $11.4M↓60% | $28.4M↑22% | $23.2M↑157% | -$40.8M↓101% | -$20.3M |
| Free Cash Flow | -$15.7M↓187% | $18.1M↑66% | $10.9M↑116% | -$68.6M↑47% | -$128.8M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Pharmaceutical Products
GLAS vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co., Inc.MRK | $364.3B | $147.76 | $65.0B | $18.3B | 34.7% | 0.94 | — | 1.54 | 2/9 | 5/9 | 4/7 | 0/3 | F-Score 4 | 1/11 |
| ABBOTT LABORATORIESABT | $188.0B | $108.52 | $44.3B | $6.5B | 12.5% | 0.25 | 18.2% | 1.58 | 3/9 | 4/9 | 2/7 | 1/3 | F-Score 5 | 3/11 |
| BRISTOL MYERS SQUIBB COBMY | $129.7B | $63.43 | $48.2B | $7.1B | 38.2% | 2.44 | 19.4% | 1.26 | 2/9 | 1/9 | 3/7 | 1/3 | F-Score 8 | 5/11 |
| BIO-TECHNE CorpTECH | $11.4B | $72.80 | $1.2B | $73.4M | 3.8% | — | 8.4% | 3.46 | 4/9 | 3/9 | 3/7 | 0/3 | F-Score 5 | 4/11 |
| REPLIGEN CORPRGEN | $10.7B | $167.79 | $738.3M | $48.9M | 2.3% | 0.26 | 7.5% | 8.37 | 3/9 | 2/9 | 3/7 | 0/3 | F-Score 7 | 5/11 |
| IONIS PHARMACEUTICALS INCIONS | $4.8B | $29.06 | $943.7M | $381.4M | -78.0% | 3.60 | -40.4% | 3.83 | 3/9 | 1/9 | 1/7 | 0/3 | F-Score 4 | 3/11 |
| NEOGEN CORPNEOG | $2.5B | $11.23 | $870.4M | $7.9M | -0.4% | 0.76 | -2.5% | 3.82 | 3/9 | 1/9 | 2/7 | 0/3 | F-Score 6 | 4/11 |
| Pharvaris N.V.PHVS | $2.4B | $33.36 | — | $206.4M | -64.8% | 0.00 | — | — | 0/9 | 0/9 | 2/7 | 0/3 | F-Score 2 | 2/11 |